Medicago Inc MDCGF

Latest positive comments on Medicago from Analyst Pooya Hemami (Desjardins Securities).

[Blueocean102]

By The Life Sciences Report, on July 11th, 2013

TLSR: Do you have any names that are breaking ground on the vaccine front?

PH:Medicago Inc. (MDG:TSX; MDCGF:OTCPK) is an emerging play in the avian flu space. It has a novel, plant-based protein manufacturing platform that can produce seasonal or pandemic flu vaccine candidates in as little as four weeks following the identification of the particular strain causing the flu. This compares to 4–6 months for conventional egg or cell culture vaccine development methods. Medicago’s quicker response timeline would be very beneficial in a pandemic scenario.

In May, Medicago announced that it was the first company to develop a vaccine candidate against H7N9 avian flu, which is responsible for the recent influenza outbreak in China. In June, it announced positive clinical data and responses with high antibody titers after only one dose in a mouse model, which we think is a very promising early result. Vaccine companies need to pass a number of trials for regulatory approval. But Medicago’s data looks promising.

FYI : full article at https://jutiagroup.com/20130711-the-growing-appetite-for-biotech-pooya-hemami/